Significance of monitoring plasma levels of amitriptyline, and its hydroxylated and desmethylated metabolites in prediction of the clinical outcome of depressive state

Psychiatry and Clinical Neurosciences

Volumn 51, Issue 1, 1997, Pages 35-41

  Shimoda, Kazutaka ^a   Yasuda, Shin ^a   Morita, Sachiyo ^a   Shibasaki, Morikazu ^a,b   Someya, Toshiyuki ^a   Bertilsson, Leif ^c   Takahashi, Saburo ^d  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b Takashima General Hospital   (Japan)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d Saitama City Hospital   (Japan)

Author keywords

amitriptyline; clinical outcome; desmethylation; discriminant analysis; hydroxylation; tricyclic antidepressants

Indexed keywords

AMITRIPTYLINE; DRUG METABOLITE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DEPRESSION; DRUG BLOOD LEVEL; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG MONITORING; FEMALE; HUMAN; MALE; MENTAL DISEASE; METHYLATION; ORAL DRUG ADMINISTRATION; PSYCHOPHARMACOTHERAPY; TREATMENT OUTCOME;

EID: 0031042214     PISSN: 13231316     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1819.1997.tb02364.x     Document Type: Article

References (45)

1. Braithwaite RA, Goulding R, Theano G, Bailey J, Coppen A. Plasma concentration of amitriptyline and clinical response. Lancet 1972; 1: 1297-1300.
2. Kupfer DJ, Hanin I, Spiker DG, Grau T, Coble P. Amitriptyline plasma levels and clinical response in primary depression. Clin. Pharmacol. Ther. 1977; 22: 904-911.
3. Ziegler VE, Co BT, Taylor JR, Clayton PJ, Biggs JT. Amitriptyline plasma levels and therapeutic response. Clin. Pharmacol. Ther. 1976; 19: 795-801.
4. Montgomery SA, McAuley R, Rani SJ, Montgomery DR, Braithwaite R, Dawling S. Amitriptyline plasma concentration and clinical response. BMJ 1979; 1: 230-231.
5. Moyes ICA, Ray RL, Moyes RB. Plasma levels and clinical improvement -a comparative study of clomipramine and amitriptyline in depression. Postgrad. Med. J. 1980; 56 (Suppl. 1): 127-129.
6. Vandel S, Vandel B, Sandoz M, Allers G, Bechtel P, Volmat R. Clinical response and plasma concentration of amitriptyline and its metabolite nortriptyline. Eur. J. Clin. Pharmacol. 1978; 14: 185-190.
7. Åsberg M, Crönholm B, Sjöqvist F, Tuck D. Relationship between plasma levels and therapeutic effect of nortriptyline. BMJ 1971; 3: 331-334.
8. Braithwaite R, Montgomery S, Dawling S. Nortriptyline in depressed patients with high plasma levels. II. Clin. Pharmacol. Ther. 1978; 23: 303-308.
9. Kragh-Sorensen P, Åsberg M, Eggert-Hansen C. Plasmanortriptyline levels in endogenous depression. Lancet 1973; 1: 113-115.
10. Montgomery S, Braithwaite R, Dawling S, McAuley R. High plasma nortriptyline levels in the treatment of depression. I. Clin. Pharmacol. Ther. 1978; 23: 309-314.
11. Ziegler VE, Clayton PJ, Taylor JR, Co BT, Biggs JT. Nortriptyline plasma levels and therapeutic response. Clin. Pharmacol. Ther. 1976; 20: 458-463.
12. Coppen A, Ghose K, Montgomery S et al. Amitriptyline plasma concentration and clinical effect: a World Health Organization collaborative study. Lancet 1978; 1: 63-66.
13. Liisberg P, Mose H, Amdisen A, Jørgensen A, Petersen HEH. A clinical trial comparing sustained release amitriptyline (Saroten Retard) and conventional amitrityline tablets (Saroten®) in endogenously depressed patients with simultaneous determination of serum levels of amitriptyline and nortriptyline. Acta Psychiatr. Scand. 1978; 57: 426-435.
14. Mendlewicz J, Linkowski P, Rees JA. A double-blind comparison of dothiepin and amitriptyline in patients with primary affective disorders: serum levels and clinical response. Br. J. Psychiatry 1980; 136: 154-160.
15. Robinson DS, Cooper TB, Ravaris CL, Ives JO, Nies A, Bartlett D, Lamborn KR. Plasma tricyclic drug levels in amitriptylinetreated depressed patients. Psychopharmacology 1979; 63: 223-231.
16. Bertilsson L, Mellström B, Sjöqvist F. Pronounced inhibition of noradrenaline uptake by 10-hydroxy-metabolites of nortriptyline. Life Sci. 1979; 25: 1285-1292.
17. Bertilsson L, Nordin C, Otani K, Resul B, Scheinin M, Siwers B. Disposition of single oral dose of E-10-hydroxynortriptyline in healthy subjects, with some observation on pharmacodynamic effects. Clin. Pharmacol. Ther. 1986; 40(261): 267.
18. Nordin C, Bertilsson L, Dahl ML, Resul B, Toresson G, Sjöqvist F. Treatment of depression with E-10-hydroxynortriptyline - a pilot study on biochemical effects and pharmacokinetics. Psychopharmacology (Berlin) 1991; 103(3): 287-290.
19. Bertilsson L, Dahl-Puustinen ML, Nordin C. E-10-hydroxynortripryline: Effects and disposition of a potential novel antidepressant. In: Dahl SG, Gram LF (eds), Clinical Pharmacology in Psychiatry. Springer-Verlag, Berlin, 1989; 52-59.
20. Bertilsson L, Aberg-Wistedt A, Liden A, Otani K, Spina E. Alprazolam does not inhibit the metabolism of nortriptyline in depressed patients or inhibit the metabolism of desipramine in human liver microsomes. Ther. Drug Monit. 1988; 10: 231-233.
21. Otani K, Nordin C, Bertilsson L. No interaction of diazepam on amitriptyline disposition in depressed patients. Ther. Drug Monit. 1987; 9: 120-122.
22. Shimoda K, Minowada T, Noguchi T, Takahashi S. Interindividual variations of desmethylation and hydroxylation of clomipramine in an Oriental psychiatric population. J. Clin. Psychopharmacol. 1993; 13: 181-188.
23. Träskman L, Bertilsson L, Åsberg M, Crönholm B, Mellström B, Neckers LM, Sjöqvist F, et al. Plasma levels of chlorimipramine and its demethyl metabolites during treatment of depression. Clin. Pharmacol. Ther. 1979; 26: 600-610.
24. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. (3rd edn revised), Washington DC, 1987.
25. Fekete J, Del Castilho P, Kraak JC. Reversed-phase liquid chromatography for the separation of chlorpromazine, imipramine and some of their metabolites. J. Chromatogr. 1981; 204: 319-327.
26. Shimoda K, Noguchi T, Morita S, Ozeki Y, Shibasaki M, Someya T, Takahashi S. Interindividual variations of desmethylation and hydroxylation of amitriptyline in a Japanese psychiatric population. J. Clin. Psychopharmacol. 1995; 15(3): 175-181.
27. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The Global Assessment Scale: A procedure for measuring overall severity of psychiatric disturbance. Arch. Gen. Psychiatry 1976; 33: 766-771.
28. Faravelli C, Ballerini A, Ambonetti A, Broadhurst AD, Das M. Plasma levels and clinical response during treatment with clomipramine. J. Affect. Disord. 1984; 6: 95-107.
29. Svanborg P, Åsberg M. A new self-rating scale for depression and anxiety states based on the Comprehensive Psychopathological Rating Scale. Acta. Psychiatr. Scand. 1994; 89: 21-28.
30. Zhang X. Serum concentrations of amitriptyline and its metabolites and clinical effect in depressive patients. Chung Hua Shen Ching Ching Shen Ko Tsa Chih 1992; 25: 196-198.
31. Robinson DS, Cooper TB, Haward D, Corcella J, Albright D. Amitriptyline and hydroxylated metabolite plasma levels in depressed outpatients. J. Clin. Psychopharmacol. 1985; 5: 83-88.
32. McCue RE, Georgotas A, Suckow A, Cooper TB. 10-hydroxynorthiptyline and treatment and effects in elderly depressed patients. J. Neuropsychiatr. Clin. Neurosci. 1989; 1: 176-180.
33. Edelbroek PM, Zitman EG, Schreuder JN, Rooymans HG, de Wolff FA. Amitriptyline metabolism in relation to antidepressive effect, Clin. Pharmacol. Ther. 1984; 35: 467-473.
34. Breyer-Pfaff U, Gaertner HJ, Kreuter F, Scharek G, Brinkschulte M, Wiatr R. Antidepressive effect and pharmacokinetics of amitriptyline with consideration of unbound drug and 10-hydroxynortriptyline plasma levels. Psychopharmacology 1982; 76: 240-244.
35. Breyer-Pfaff U, Giedke H, Gaertner HJ, Nill K. Validation of a therapeutic plasma level range in amitriptyline treatment of depression. J. Clin. Psychopharmacol. 1989; 9(2): 116-121.
36. Noguchi T, Shimoda K, Takahashi S. Clinical significance of plasma levels of clomipramine, its hydroxylated and desmethylated metabolites: prediction of clinical outcome in mood disorders using discriminant analysis of therapeutic drug monitoring data. J. Affect. Disord. 1993; 29: 267-279.
37. Bertilsson L, Alexanderson B. Stereospecific hydroxylation of nortriptyline in man in relation to interindividual differences in its steady state plasma levels. Eur. J. Clin. Pharmacol. 1972; 4: 201-205.
38. Mellström B, Bertilsson L, Sawe J, Achulz HU, Sjöqvist F. E- and Z-hydroxylation of nortriptyline: Relationship to polymorphic debrisoquine hydroxylation. Clin. Pharmacol. Ther. 1981; 30: 189-193.
39. Gram LF. Inadequate dosing and pharmacokinetic variability as confounding factors in assessment of efficacy of antidepressants. Clin. Neuropharmacol. 1990; 13 (Suppl. 1): 35-45.
40. Burch JE, Ahmed O, Hullin RP, Mindham RHS. Antidepressive effect of amitriptyline treatment with plasma drug levels controlled within three different ranges. Psychopharmacology 1988; 94: 197-205.
41. Kragh-Sørensen P, Hansen CE, Baastrup PC, Hvidberg EF. Self-inhibiting action of nortriptyline's antidepressive effect at high plasma levels. A randomized double-blind study controlled by plasma concentrations in patients with endogenous depression. Psychopharmacologia (Berlin) 1976; 46: 305-312.
42. Yamada R. Characteristics and choice of antidepressants. 1. In: Tsutsui S et al. (eds), Tricyclic antidepressants. Advances in antidepressants. Igaku Journal-Sya, Tokyo, 1992; 39-50.
43. Solomon RL, Rich CL, Darko DF. Antidepressant treatment and occurrence of mania in bipolar patients admitted for depression. J. Affect. Disord. 1990; 18: 253-257.
44. Roose SP, Glassman AH, Attia E, Woodring S. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am. J. Psychiatry 1994; 151: 1735-1739.
45. Schmider J, Deuschle M, Schweiger U, Körner A, Gotthardt U, Heuser IJ. Amitriptyline metabolism in elderly depressed patients and normal controls in relation to hypothalamic-pituitary-adrenal system function. J. Clin. Psychopharmacol. 1995; 15(4): 250-258.